Literature DB >> 10412020

Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease.

L Ho1, C Pieroni, D Winger, D P Purohit, P S Aisen, G M Pasinetti.   

Abstract

Cyclooxygenase-2 (COX-2), a key enzyme in prostanoid biosynthesis, may represent an important therapeutic target in Alzheimer's disease (AD). In the present study, we explored the regulation of COX-2 in the hippocampal formation in sporadic AD. Using semiquantitative immunocytochemical techniques, we found that in AD cases (vs. age-matched controls) neurons of the CA1-CA4 subdivisions of the hippocampal pyramidal layer showed elevation of COX-2 signal; COX-2 levels correlated with amyloid plaque density. In contrast, the level of COX-2 immunostaining in the dentate gyrus granule neurons was not elevated in AD. No expression of COX-2 in cells with glial morphology was found in any case examined. In parallel, in vitro studies found that neurons derived from transgenic mice with neuronal overexpression of COX-2 are more susceptible to beta-amyloid (Abeta) toxicity, with potentiation of redox impairment. The results indicate elevated expression of neuronal COX-2 in subregions of the hippocampal formation in AD and that such elevation may potentiate Abeta-mediated oxidative stress. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412020     DOI: 10.1002/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  39 in total

1.  Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling.

Authors:  Walter J Lukiw
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

2.  Pharmacotherapy in the treatment of Alzheimer's disease: an update.

Authors:  Brian E Leonard
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

Review 3.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

Review 5.  Cyclooxygenase-2 in synaptic signaling.

Authors:  Hongwei Yang; Chu Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

6.  COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation.

Authors:  A Straiker; J Wager-Miller; S S Hu; J L Blankman; B F Cravatt; K Mackie
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 7.  Oxidative stress and inflammation in brain aging: nutritional considerations.

Authors:  J A Joseph; B Shukitt-Hale; G Casadesus; D Fisher
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 8.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

Review 9.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

10.  Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.

Authors:  Johannes C M Schlachetzki; Bernd L Fiebich; Elisabeth Haake; Antonio C P de Oliveira; Eduardo Candelario-Jalil; Michael T Heneka; Michael Hüll
Journal:  J Neuroinflammation       Date:  2010-01-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.